Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gianantonio Rosti

Showing results (11-20 of 153) with videos related to

Pageof 16
Sort By:
Expert Review of Hematology|March 27, 2014
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemiaMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
The Oncologist|June 3, 2011
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?Simona Soverini, Gianantonio Rosti, Ilaria Iacobucci, et al.
Mediterranean Journal of Hematology and Infectious Diseases|January 24, 2014
Treatment recommendations for chronic myeloid leukemiaMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Pharmacogenomics|August 28, 2012
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysisSimona Soverini, Giovanni Martinelli, Gianantonio Rosti, et al.
Oncotargets and Therapy|December 3, 2010
Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristicsKimbach Tran Carpiuc, Gianantonio Rosti, Fausto Castagnetti, et al.
Leukemia & Lymphoma|March 23, 2010
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Journal of Blood Medicine|December 11, 2012
First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluationPier Paolo Piccaluga, Stefania Paolini, Clara Bertuzzi, et al.
Expert Review of Hematology|October 3, 2013
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitorsGabriele Gugliotta, Fausto Castagnetti, Miriam Fogli, et al.
Cell Cycle (Georgetown, Tex.)|April 12, 2011
Explaining the in vitro and in vivo differences in leukemia therapyTom Lenaerts, Fausto Castagnetti, Arne Traulsen, et al.
Expert Opinion on Biological Therapy|October 6, 2007
Imatinib mesylate in the treatment of hematologic malignanciesPier Paolo Piccaluga, Michela Rondoni, Stefania Paolini, et al.
Pageof 16

Showing results (11-20 of 153) with videos related to

Sort By:
Pageof 16
Expert Review of Hematology|March 27, 2014
Definition and treatment of resistance to tyrosine kinase inhibitors in chronic myeloid leukemiaMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
The Oncologist|June 3, 2011
Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?Simona Soverini, Gianantonio Rosti, Ilaria Iacobucci, et al.
Mediterranean Journal of Hematology and Infectious Diseases|January 24, 2014
Treatment recommendations for chronic myeloid leukemiaMichele Baccarani, Fausto Castagnetti, Gabriele Gugliotta, et al.
Pharmacogenomics|August 28, 2012
Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysisSimona Soverini, Giovanni Martinelli, Gianantonio Rosti, et al.
Oncotargets and Therapy|December 3, 2010
Indirect comparisons of second-generation tyrosine kinase inhibitors in CML: case study using baseline population characteristicsKimbach Tran Carpiuc, Gianantonio Rosti, Fausto Castagnetti, et al.
Leukemia & Lymphoma|March 23, 2010
Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a 'head-to-head comparison'Gianantonio Rosti, Fausto Castagnetti, Gabriele Gugliotta, et al.
Journal of Blood Medicine|December 11, 2012
First-line treatment of chronic myeloid leukemia with nilotinib: critical evaluationPier Paolo Piccaluga, Stefania Paolini, Clara Bertuzzi, et al.
Expert Review of Hematology|October 3, 2013
Impact of comorbidities on the treatment of chronic myeloid leukemia with tyrosine-kinase inhibitorsGabriele Gugliotta, Fausto Castagnetti, Miriam Fogli, et al.
Cell Cycle (Georgetown, Tex.)|April 12, 2011
Explaining the in vitro and in vivo differences in leukemia therapyTom Lenaerts, Fausto Castagnetti, Arne Traulsen, et al.
Expert Opinion on Biological Therapy|October 6, 2007
Imatinib mesylate in the treatment of hematologic malignanciesPier Paolo Piccaluga, Michela Rondoni, Stefania Paolini, et al.
Pageof 16